Analyst Ratings for Auxilium Pharmaceuticals (AUXL) [Buys]
AUXL Rating Summary
AUXL Price Target Summary
- Highest: $37.00 (Aegis Capital)
- Lowest: $13.00 (Brean Capital)
- Average: $25.83
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$25.83 (+70.2%)
Avg. $ Target:
$25.83 (+70.2%)
| Date | Firm | Type | Rating (Past) |
PT (Past) |
Start $ | End $ | % Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/30/2013 | Stifel Nicolaus | Upgrade | Buy (Hold) |
N/A (N/A) |
14.00 | 15.18 | 8.43% | Details |
| 10/8/2012 | WallachBeth Capital | New Coverage | Buy (N/A) |
32.00 (N/A) |
24.50 | 15.18 | -38.04% | Details |
| 8/16/2012 | Aegis Capital | New Coverage | Buy (N/A) |
37.00 (N/A) |
24.26 | 15.18 | -37.43% | Details |
| 3/26/2012 | Canaccord Genuity » Updated 8/1/2012 |
New Coverage | Buy (N/A) |
33.00 (27.00) |
18.50 | 15.18 | -17.95% | Details |
| 1/18/2012 | RBC Capital | Upgrade | Outperform (N/A) |
26.00 (N/A) |
19.73 | 15.18 | -23.06% | Details |
| 10/19/2011 | Collins Stewart | Upgrade | Buy (N/A) |
23.00 (N/A) |
16.60 | 15.18 | -8.55% | Details |
| 9/28/2011 | Citi | Upgrade | Buy (N/A) |
25.00 (N/A) |
14.51 | 15.18 | 4.62% | Details |
| 4/15/2011 | UBS » Updated 8/21/2012 |
New Coverage | Buy (N/A) |
34.00 (32.00) |
22.44 | 15.18 | -32.35% | Details |
